Takeda claims PhIII success in dengue vaccine months after Dengvaxia implosion for rival Sanofi
Takeda is one stride closer to reaching the sizable market waiting for dengue vaccines as it reports positive top-line results from a massive Phase III trial.
The analysis, which constitutes the first of a three-part study, concludes that the company’s tetravalent dengue vaccine TAK-003 was efficacious at 15 months in preventing dengue fever caused by any of the four serotypes of the virus, thereby meeting the primary endpoint. And while they are saving the details for a peer-reviewed journal, Takeda $TAK researchers say the vaccine was “well tolerated with no significant safety concerns to date.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
